Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume - Time to Buy?

Key Points

• Inventiva’s trading volume surged 196% to approximately 2.86 million shares, while the stock traded near $2.97, modestly above its prior close.
• Analysts remain broadly positive, with an average “Buy” rating and a $15.86 price target; coverage includes two Strong Buy and seven Buy ratings, alongside one Sell rating.
• Inventiva is a clinical-stage biopharmaceutical company developing lanifibranor, an investigational treatment for MASH currently being evaluated in the Phase 3 NATiV3 trial. The company reported a quarterly loss of $0.14 per share and $0.75 million in revenue.

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) saw unusually-strong trading volume on Monday. Approximately 2,856,577 shares traded hands during mid-day trading, an increase of 196% from the previous session's volume of 966,662 shares. The stock last traded at $2.9650 and had previously closed at $2.94.

Wall Street Analyst Weigh In

IVA has been the subject of several analyst reports. Piper Sandler restated an "overweight" rating on shares of Inventiva in a report on Wednesday, September 16th. Truist Financial raised their price objective on shares of Inventiva from $13.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, October 2nd. Guggenheim lifted their target price on shares of Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, September 15th. Cantor Fitzgerald started coverage on Inventiva in a research report on Friday, July 17th. They issued an "overweight" rating on the stock. Finally, Wall Street Zen upgraded Inventiva from a "sell" rating to a "hold" rating in a research note on Saturday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $15.86.

Inventiva Price Performance

The firm has a 50-day simple moving average of $4.04 and a 200-day simple moving average of $4.46.

Inventiva (NASDAQ:IVA - Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The company had revenue of $0.75 million for the quarter. As a group, equities analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Inventiva

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP purchased a new position in Inventiva during the first quarter valued at approximately $1,111,000. Engineers Gate Manager LP boosted its holdings in Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company's stock worth $269,000 after buying an additional 43,280 shares during the period. Finally, Platt Investment Counsel LLC bought a new position in Inventiva in the 3rd quarter worth $45,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.